1. Liu, Heng-Jia, Du, Heng, Khabibullin, Damir, Kwiatkowski, David J, Henske, Elizabeth P. 2023. mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. In Nature communications, 14, 1214. doi:10.1038/s41467-023-36881-7. https://pubmed.ncbi.nlm.nih.gov/36869048/
2. Zhang, Caihua, Li, Kang, Zhu, Hongzhang, Wang, Cheng, Chen, Demeng. 2024. ITGB6 modulates resistance to anti-CD276 therapy in head and neck cancer by promoting PF4+ macrophage infiltration. In Nature communications, 15, 7077. doi:10.1038/s41467-024-51096-0. https://pubmed.ncbi.nlm.nih.gov/39152118/
3. Fu, Minjie, Zhang, Jinsen, Li, Weifeng, Hua, Wei, Mao, Ying. 2021. Gene clusters based on OLIG2 and CD276 could distinguish molecular profiling in glioblastoma. In Journal of translational medicine, 19, 404. doi:10.1186/s12967-021-03083-y. https://pubmed.ncbi.nlm.nih.gov/34565408/
4. Takashima, Yasuo, Kawaguchi, Atsushi, Hayano, Azusa, Yamanaka, Ryuya. 2019. CD276 and the gene signature composed of GATA3 and LGALS3 enable prognosis prediction of glioblastoma multiforme. In PloS one, 14, e0216825. doi:10.1371/journal.pone.0216825. https://pubmed.ncbi.nlm.nih.gov/31075138/
5. Kendsersky, Nathan M, Lindsay, Jarrett, Kolb, E Anders, Houghton, Peter J, Maris, John M. 2021. The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. In Clinical cancer research : an official journal of the American Association for Cancer Research, 27, 2938-2946. doi:10.1158/1078-0432.CCR-20-4221. https://pubmed.ncbi.nlm.nih.gov/33619171/
智鼠故事 
